



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

UMAÑA *et al.*

Appl. No.: 10/633,699

Filed: August 5, 2003

For: **Glycosylation Engineering of
Antibodies for Improving
Antibody-Dependent Cellular
Cytotoxicity**

Confirmation No.: 5489

Art Unit: 1633

Examiner: Riggins, Patrick S.

Atty. Docket: 1975.0010004/TJS/T-M

**Second Supplemental Information Disclosure Statement
Filing under 37 C.F.R. § 1.97(c)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

07/25/2006 SDENBOB1 00000108 10633699

02 FC:1806

180.00 QP

Sir:

Listed on accompanying Form PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on July 18, 2005, in connection with the above-captioned application. Copies of the documents listed on accompanying Form PTO/SB/08B are submitted herewith.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Form PTO/SB/08B based on information presently available to the undersigned. However, the listed

publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form, which includes payment in the amount of \$180.00 for the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO/SB/08B, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Timothy J. Shea, Jr.
Attorney for Applicants
Registration No. 41,306

Date: July 24, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

555936_1.DOC



Under the Paperless Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/633,699
				Filing Date	August 5, 2003
				First Named Inventor	Pablo UMAÑA
				Art Unit	1633
				Examiner Name	Riggins, Patrick S.
Sheet	1	of	1	Attorney Docket Number	1975.0010004/TJS/T-M

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published		T ²
	AT51	Edge, C.J., <i>et al.</i> , "The conformational effects of N-linked glycosylation," <i>Biochem. Soc. Trans.</i> 21:452-455, Portland Press (1993)		
	AR52	Jefferis, R. and Lund, J., "Glycosylation of Antibody Molecules: Structural and Functional Significance," <i>Chem. Immunol.</i> 65:111-128, Karger (January 1997)		
	AS52	Jefferis, R., <i>et al.</i> , "Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects," <i>Ann. Biol. Clin.</i> 52:57-65, John Libbey Eurotext (1994)		
	AT52	Jefferis, R., <i>et al.</i> , "IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation," <i>Immunol. Rev.</i> 163:59-76, Munksgaard (June 1998)		
	AR53	Nakamura, K. <i>et al.</i> , "Chimeric Anti-Ganglioside G _{M2} Antibody with Antitumor Activity," <i>Cancer Research</i> 54:1511-1516, American Association for Cancer Research (1994)		
	AS53	Routier, F.H. <i>et al.</i> , "The glycosylation pattern of a humanized IgG1 antibody (D1.3) expressed in CHO cells," <i>Glycoconjugate J.</i> 14:201-207, Chapman & Hall (February 1997)		
	AT53	Shitara, K., <i>et al.</i> , "A new vector for the high level expression of chimeric antibodies in myeloma cells," <i>J. Immunol. Methods</i> 167:271-278, Elsevier Science (1991)		
	AR54	Standley, S. and Baudry, M., "The role of glycosylation in ionotropic glutamate receptor ligand binding, function, and trafficking," <i>Cell. Mol. Life Sci.</i> 57:1508-1516, Birkhäuser Verlag (October 2000)		
	AS54	Standley, P., <i>et al.</i> , "CHO cells provide access to novel N-glycans and developmentally regulated glycosyltransferases," <i>Glycobiol.</i> 6:695-699, Oxford University Press (1996)		
	AT54	Youakim, A. and Shur, B.D., "Alteration of Oligosaccharide Biosynthesis by Genetic Manipulation of Glycosyltransferases," <i>Ann. N.Y. Acad. Sci.</i> 745:331-335, New York Academy of Sciences (1994)		

555945_1.DOC

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.